At Johnson & Johnson, the world’s largest health care company, products or business that aren’t top performers aren’t lasting very long. About 70 percent of sales come from assets that were either No. 1 or No. 2 in their category. Last …
Under the ASR agreements Janssen Pharmaceutical will purchase shares of Johnson & Johnson common stock that the banks will have borrowed from stock lenders, and during the term of the ASR agreements the banks are expected to …
George Leong: Johnson & Johnson (NYSE:JNJ), which is one of my favorite long-term stocks for income and dividend-reinvesting investors, just dropped below the $100.00-per-share level and is becoming more attractive each day. This …
SOMERVILLE, N.J., Aug. 23-- Johnson and Johnson issued the following news release: Spectrum Health realized …
Shares of Actelion Ltd.(ALIOF.PK) were gaining around 21 percent in the morning trading after the Swiss biotechnology firm on Thursday agreed to a $30 billion takeover by drug major Johnson & Johnson (JNJ). Immediately prior to the …
JNJ) traded up 2.15% at $136.78. The stock’s 52-week range is $109.32 to $137.08. Volume was about 60% above the daily average of around 5.1 million. Jefferies raised the stock’s rating from Hold to Buy and lifted the price target from …
Johnson & Johnson’s bid for Synthes, a Swiss-American medical equipment manufacturer, makes a lot of strategic sense. The $21.3 billion deal will give Johnson & Johnson a leading position in the main orthopedic device markets. …
Information contained on this page is provided by an independent third-party content provider. Frankly and this Site …
Johnson & Johnson (JNJ.N) shares have beaten the group in 2016 as investors turn to safety in rocky equity markets. But with the stock price now hovering near its $110.35 record high, that strategy may be in doubt. J&J shares already …
Unexpectedly strong earnings reports from heavyweights like Mattel and Johnson & Johnson streamed in on Tuesday, …